Hugo Boss Raises $185 Million for Investment Plan
By Andrea Figueras
Hugo Boss has raised 175 million euros ($185.3 million) to finance further investments as part of its growth strategy 'CLAIM 5' aimed at accelerating growth across all brands, touchpoints and geographies.
The German premium-fashion firm raised the proceeds via a schuldschein loan--a financial instrument similar to a bond, but which doesn't need to be registered at a stock exchange--after the initial target volume of EUR100 million was significantly exceeded due to high demand.
The loan comprises 4 tranches with maturities of 3 and 5 years, each of which was offered with fixed and variable interest rates, Hugo Boss said.
More than 70 institutional investors participated in the financing, with high demand in Europe and Asia, it said.
The transaction was arranged by DZ Bank AG and Landesbank Baden-Wuerttemberg, the company said.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
October 25, 2023 05:26 ET (09:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track